Amylyx Pharmaceuticals In... (AMLX)
NASDAQ: AMLX
· Real-Time Price · USD
13.42
0.13 (0.98%)
At close: Oct 03, 2025, 3:59 PM
13.66
1.79%
After-hours: Oct 03, 2025, 05:51 PM EDT
0.98% (1D)
| Bid | 12.9 |
| Market Cap | 1.2B |
| Revenue (ttm) | -249K |
| Net Income (ttm) | -187.6M |
| EPS (ttm) | -2.4 |
| PE Ratio (ttm) | -5.59 |
| Forward PE | -9.43 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 14.08 |
| Volume | 1,186,631 |
| Avg. Volume (20D) | 2,188,041 |
| Open | 13.57 |
| Previous Close | 13.29 |
| Day's Range | 13.21 - 13.72 |
| 52-Week Range | 2.60 - 15.14 |
| Beta | -0.33 |
| Ex-Dividend Date | n/a |
About AMLX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AMLX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AMLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+12.56%
Amylyx Pharmaceuticals shares are trading higher. ...
Unlock content with
Pro Subscription
2 months ago
+9.51%
Amylyx Pharmaceuticals shares are trading higher after the company highlighted the efficacy and 24-hour coverage of Avexitide 90 mg daily and announced it supports advancing to Phase 3 of the LUCIDITY trial.
